Mikhail Kosiborod

Mikhail Kosiborod

Professor of Medicine

MD FAHA FACC

University of Missouri-Kansas City, Kansas City, US

  • LinkedIn
  • X

Biography

Dr Mikhail Kosiborod is a cardiologist based in the United States, where he serves as Senior Vice President, Late-stage Development, CVRM at AstraZeneca and Professor of Medicine at the University of Missouri–Kansas City. He is internationally recognised for his work at the intersection of cardiovascular disease, diabetes, and metabolic disorders, and has built a career that integrates clinical care, research leadership, and academic medicine.

 

Academic History

Dr Kosiborod holds an academic appointment as Professor of Medicine at the University of Missouri–Kansas City. His academic career has focused on advancing understanding of cardiometabolic and cardiorenal disease, with a particular emphasis on improving outcomes for patients with diabetes and cardiovascular disease through translational research and large-scale clinical trials.

 

Career Overview

Dr Mikhail Kosiborod plays a central leadership role in cardiovascular and metabolic research. He is Director of Cardiometabolic Research and Co-Director of the Saint Luke’s Michael & Marlys Haverty Cardiometabolic Center of Excellence at Saint Luke’s Mid America Heart Institute. In these roles, he oversees a broad portfolio of clinical and translational research initiatives focused on diabetes, cardiovascular disease, and related metabolic conditions.

He is an internationally recognised expert in cardiometabolic and cardiorenal syndromes and is actively involved in the leadership of numerous large-scale clinical trials and multi-center registries. Dr Kosiborod currently serves as principal investigator for several investigator-initiated, multi-center trials in diabetes and cardiovascular disease, contributing to the development of evidence that informs clinical guidelines and patient care worldwide.

 

Career Timeline

  • Appointed Professor of Medicine at the University of Missouri–Kansas City
  • Appointed Vice President of Research at Saint Luke’s Health System
  • Appointed Director of Cardiometabolic Research at Saint Luke’s Mid America Heart Institute
  • Appointed Co-Director of the Michael & Marlys Haverty Cardiometabolic Center of Excellence
  • Ongoing leadership of multi-center clinical trials and registries in diabetes and cardiovascular disease

 

Recognition

Dr Kosiborod is widely recognised for his contributions to research in diabetes, cardiovascular disease, and cardiometabolic medicine. His work has helped shape contemporary understanding of the links between metabolic disorders and cardiovascular outcomes, and he is frequently invited to contribute to international scientific meetings, guideline initiatives, and collaborative research efforts.

 

Areas of Speciality

  • Cardiovascular disease
  • Diabetes and cardiovascular risk
  • Cardiometabolic syndromes
  • Cardiorenal syndromes
  • Clinical trials and outcomes research
  • Translational and investigator-initiated research

 

References

Read more

Media

Obesity as a Disease, Diagnosis and Cardiovascular Disease Risk

Naveed Sattar, Harold Bays, Mikhail Kosiborod, et al

Watch time: 1h 1m
AHA 24 Late-Breaking Discussion: REALIZE-K

Harriette Van Spall, Mikhail Kosiborod

Watch time: 22m 30s
HFSA 24: STEP-HFpEF: Exercise Function and Frailty Status

Mikhail Kosiborod

Watch time: 12m 9s

Harold Bays, Naveed Sattar, Lydia Alexander, et al

HFA 24 Late-Breaker Discussion: Insights from the STEP-HFpEF

Harriette Van Spall, Mikhail Kosiborod

Watch time: 12m 4s
ACC.24: The STEP HFpEF DM Trial

Mikhail Kosiborod

Watch time: 6m 41s

Broadcast

Prevention & Chronic Conditions

Cardiovascular Renal Metabolic
AOM 2024

Harold Bays, Naveed Sattar, Mikhail Kosiborod, et al

ESC 23 Late-Breaker Discussion: The STEP HFpEF Trial

Harriette Van Spall, Mikhail Kosiborod

Watch time: 13m 24s

Mikhail Kosiborod, Shelley Zieroth, Andrew JS Coats, et al

Watch time: 49m 50s (8 videos)

Mikhail Kosiborod, Shelley Zieroth

Watch time: 19m 6s (3 videos)
Heart Failure in Focus - Ep 5

Muthiah Vaduganathan, Mikhail Kosiborod,

Listen time: 23m 6s

Andrew JS Coats, Mikhail Kosiborod

Watch time: 17m 31s (3 videos)
Masterclass: Evidence on the Use of SGLT2is in HF Across the EF Spectrum

Scott Solomon, Harriette Van Spall, Mikhail Kosiborod, et al

Watch time: 29m 37s

Biykem Bozkurt, Andrew JS Coats, Mikhail Kosiborod

Watch time: 51m 41s (3 videos)
HF 22: 2022 Heart Failure Highlights with Dr Kosiborod

Mikhail Kosiborod

Watch time: 4m 5s

Mikhail Kosiborod, Joanna Osmanska, Cecilia Linde, et al

Watch time: 46m 15s (12 videos)
HF 22: Findings from the Pooled Analysis of DEFINE-HF and PRESERVED-HF

Mikhail Kosiborod

Watch time: 6m 12s

Shelley Zieroth, Andrew JS Coats, Javed Butler, et al

Giuseppe Rosano, Mikhail Kosiborod, Biykem Bozkurt

Watch time: 18m 38s (3 videos)
ACC/AHA/HFSA Guideline for the Management of Heart Failure

Mikhail Kosiborod, Harriette Van Spall

Watch time: 3m 14s
ACC 22: Results From the EMPULSE Study

Mikhail Kosiborod

Watch time: 5m 35s
Incretin Management in Type 2 Diabetes

Mikhail Kosiborod, Silvio Inzucchi, Kamlesh Khunti, et al

Mikhail Kosiborod, Dalane W Kitzman

Watch time: 36m 12s (5 videos)
The PRESERVED-HF Study

Mikhail Kosiborod

Watch time: 12m 4s

Federico M Asch, Jan Belohlavek, Rupert Bauersachs, et al

Watch time: 4h 24m 8s (20 videos)
ACC 2021: The DARE-19 Randomized Trial

Mikhail Kosiborod

Watch time: 15m 45s
thumbnail

Mikhail Kosiborod, Arun Sanyal

Watch time: 10m 33s
thumbnail

Mikhail Kosiborod, Arun Sanyal

Watch time: 20m 54s
End of Year COVID update with Dr Mikhail Kosiborod and Dr Shelley Zieroth

Mikhail Kosiborod, Shelley Zieroth

Watch time: 23m 27s
Year End Video With Dr Mikhail Kosiborod And Dr Silvio Inzucchi

Mikhail Kosiborod, Silvio Inzucchi

Watch time: 29m 18s

Mikhail Kosiborod, Mark Petrie

Watch time: 31m 36s (3 videos)
DAPA-HF Background Therapy

Mikhail Kosiborod, Mark Petrie

Watch time: 25m 36s
AHA 2019: Updates from the DAPA-HF trial — Dr Harriette Van Spall and Dr Mikhail N Kosiborod

Harriette Van Spall, Mikhail Kosiborod

Watch time: 7m 44s

Andrew JS Coats, Carolyn Lam, Felipe Martínez, et al

Watch time: 57m 59s (6 videos)
EASD 2019: The DEFINE-HF trial - Dr Mikhail N Kosiborod

Mikhail Kosiborod

Watch time: 7m 49s
DAPA-HF: A discussion with the trialist

John JV McMurray, Mikhail Kosiborod

Watch time: 19m 18s
ACC 2018: SGLT-2 Inhibitors Versus Other Glucose Lowering Drugs

Mikhail Kosiborod

Watch time: 10m 16s